Results 51 to 60 of about 20,176 (178)
Drug Design, Development and Therapy, 2017 Chang Hee Kim,1 Hyungmi An,2 Sung Hye Kim,3 Dongseong Shin4 1Department of Urology, Gachon University Gil Medical Center, Incheon, 2Department of Statistics, Seoul National University, Seoul, 3Clinical Development, Navipharm Co., Ltd., Suwon ...
Kim CH, An H, Kim SH, Shin D
doaj
Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes
Journal of Lipid Research, 2009 Catabolism of HDL particles is accelerated in type 2 diabetes, leading to a reduction in plasma residence time, which may be detrimental. Rosuvastatin is the most powerful statin to reduce LDL-cholesterol, but its effects on HDL metabolism in type 2 ...
Bruno Vergès +8 more
doaj +1 more source
Rosuvastatin-Induced Thrombocytopenia
Southern Medical Journal, 2010 Rosuvastatin, a statin indicated for patients with primary hypercholesterolemia, mixed dyslipidemia and familial hypercholesterolemia, is well tolerated by most patients. Its most common adverse effects are gastrointestinal derangement, muscle aches and hepatitis. One rare complication of statin treatment is severe thrombocytopenia.
Vrettos, I. +7 more
openaire +3 more sources
Genomic and Sex Contributions to Interindividual Variability in Pitavastatin Bioavailability
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.ABSTRACT Aim This study investigates pharmacogenetic determinants of pitavastatin disposition using a candidate‐gene approach. Methods In 48 healthy volunteers, 138 variants across 40 genes involved in drug metabolism and transport were analysed to assess their relationship with pitavastatin pharmacokinetics, alongside the influence of sex and ...
Eva González‐Iglesias +7 more
wiley +1 more source
Acta Chimica Slovenica, 2017 An ultra-performance liquid chromatographic method for simultaneous determination of rosuvastatin and rosuvastatin degradation products was developed and optimized by using fractional factorial experimental design.
Jure Zakrajšek +3 more
doaj +2 more sources
ClinicoEconomics and Outcomes Research, 2015 Furio Colivicchi,1 Catarina Sternhufvud,2 Sanjay K Gandhi3 1Cardiology Division, Emergency Department, San Filippo Neri Hospital, ASL Roma E, Rome, Italy; 2Global Payer Evidence and Pricing, AstraZeneca R&D, Mölndal, Sweden; 3Global Health ...
Colivicchi F, Sternhufvud C, Gandhi SK
doaj
Clinical, Radiographic, and Histopathologic Features of Human Perigraftitis
Journal of Esthetic and Restorative Dentistry, Volume 38, Issue 7, Page 1300-1314, July 2026.ABSTRACT Objective Perigraftitis is a biologic complication associated with dental implants placed in grafted bone, distinct from peri‐implant mucositis and peri‐implantitis. This report further characterizes its clinical, radiographic, and histopathologic features.
Jonathan H. Do +2 more
wiley +1 more source
Drug Design, Development and Therapy, 2015 Jin Ah Jung,1 Soo-Yun Lee,2 Jung-Ryul Kim,1 Jae-Wook Ko,1,2 Seong Bok Jang,3 Su Youn Nam,3 Wooseong Huh1,41Department of Clinical Pharmacology and Therapeutics, Samsung Medical Center, 2Department of Health Sciences and Technology, Samsung Advanced ...
Jung JA +6 more
doaj
Physiological Reports, Volume 14, Issue 13, July 2026.Physically active adults with uncomplicated type 1 diabetes and healthy controls completed incremental cycling cardiopulmonary exercise testing with measurements at rest, ventilatory thresholds 1 and 2, and peak exercise. Linear mixed‐effects models showed no statistically detectable Group effects or Group × Stage interactions for conventional ...
Samu Sorola +7 more
wiley +1 more source
Clinical Interventions in Aging, 2013 Zhen Wang, Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai, People's Republic of ChinaAbstract: Coronary heart disease (CHD) is the leading cause of death worldwide.
Wang Z, Ge JB
doaj